those w/ underlying cancer are at high risk poor outcomes covid-19. see subgroup analysis pfizer &amp; biontechâ€™s ph3 trial assessing efficacy &amp; safety their mrna #covid19 vaccine healthy participants w/ past/active neoplasm w/ 6mo follow-up